Atara Biotherapeutics (ATRA) Earnings Date, Estimates & Call Transcripts $10.46 +0.11 (+1.06%) (As of 01:04 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Atara Biotherapeutics Latest Earnings SummaryActual EPS (Nov. 12) -$2.93 Beat By $0.84 Consensus EPS (Nov. 12) -$3.77 Atara Biotherapeutics released Q3 2024 earnings on November 12, 2024, reporting an EPS of -$2.93, which beat the consensus estimate of -$3.77 by $0.84. Quarterly revenue was reported to be $40.19 million, above analysts' expectations of $23 million. With a trailing EPS of -$25.78, Atara Biotherapeutics' earnings are expected to decrease next year, from ($12.12) to ($15.63) per share. Earnings Press ReleaseEarnings Slide DeckPowered by Get Atara Biotherapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataATRA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ATRA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Atara Biotherapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.62-$0.62-$0.62Q2 20241$0.06$0.06$0.06Q3 20241-$4.67-$4.67-$4.67Q4 20241-$8.63-$8.63-$8.63FY 20244-$13.86-$13.86-$13.86Q1 20251$3.05$3.05$3.05Q2 20251-$8.08-$8.08-$8.08Q3 20251-$7.84-$7.84-$7.84Q4 20251-$7.62-$7.62-$7.62FY 20254($20.49)($20.49)($20.49) Atara Biotherapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/12/2024Q3 2024-$3.77-$2.93+$0.84-$2.93$23.00M$40.19M8/12/2024Q2 2024-$1.56-$3.10 -$1.54-$3.10$48.30M$28.64M5/9/2024Q1 2024-$9.25-$5.75+$3.50-$0.23$27.00M$27.36M3/28/2024Q4 2023-$15.25-$14.00+$1.25-$0.56$2.45M$4.25M11/1/2023Q3 2023-$15.75-$16.50 -$0.75-$0.66$2.20M$2.14M8/8/2023Q2 2023-$16.25-$17.00 -$0.75-$0.68$3.36M$0.96M Get the Latest News and Ratings for ATRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/8/2023Q1 2023-$10.00-$18.00 -$8.00-$0.72$37.67M$1.23M2/8/2023Q4 2022-$15.25-$18.00 -$2.75-$0.72$60.00M$0.22M Atara Biotherapeutics Earnings - Frequently Asked Questions When did Atara Biotherapeutics announce their last quarterly earnings? Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earning data on Tuesday, November 12, 2024. Learn more on ATRA's earnings history. Did Atara Biotherapeutics beat their earnings estimates last quarter? In the previous quarter, Atara Biotherapeutics (NASDAQ:ATRA) reported ($2.93) earnings per share (EPS) to beat the analysts' consensus estimate of ($3.77) by $0.84. Learn more on analysts' earnings estimate vs. ATRA's actual earnings. How much revenue does Atara Biotherapeutics generate each year? Atara Biotherapeutics (NASDAQ:ATRA) has a recorded annual revenue of $100.44 million. How much profit does Atara Biotherapeutics generate each year? Atara Biotherapeutics (NASDAQ:ATRA) has a recorded net income of -$276.13 million. ATRA has generated -$25.78 earnings per share over the last four quarters. What is Atara Biotherapeutics's EPS forecast for next year? Atara Biotherapeutics's earnings are expected to decrease from ($12.12) per share to ($15.63) per share in the next year. More Earnings Resources from MarketBeat Related Companies FULC Earnings ACB Earnings FATE Earnings LXEO Earnings DMAC Earnings ZNTL Earnings ATAI Earnings TNYA Earnings ACRS Earnings ACRV Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings The #1 Coin for November 2024 (Ad)‘Gift’ Yourself a Potential 10,000% Win! #1 Crypto to Buy Before 2025 REVEALED! Click here to get all the details on this crypto coin now. This page (NASDAQ:ATRA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
